News | January 06, 2026
PathoCare Holdings valued at $1.75 billion following major third-party tender offer
The company previously completed a $150 million venture investment, acquisition, and recapitalization
The company previously completed a $150 million venture investment, acquisition, and recapitalization
He noted the enduring relevance of Siddha medicine as “a comprehensive, preventive and sustainable healthcare system in the contemporary world
Leaders from science, policy, industry, and investment came together in New Delhi to examine how alignment across the biotechnology value chain can turn innovation into outcomes at scale
The collaboration aims to combine synthetic biology with cutting-edge detection technology to create a first-of-its-kind oral pill embedded with tumor-targeting sensors
Ushio, a leader in advanced optical technologies, brings a strong track record and proprietary Photobonding technology
Study published in laboratory investigation, the official journal of the United States and Canadian Academy of Pathology
The platform aims to serve doctors, consumers, and healthcare facilities by providing AI-assisted clinical decision tools, personalized health insights, and improved diagnostic capabilities
Using a combination of blood and faecal samples, the service examines key biomarkers, including hereditary genetic status
,_Thyrocare_256_384.jpg)
Dr Kinha is a seasoned healthcare and diagnostics leader with over 17 years of experience across leading organisations in the diagnostics sector, with deep expertise in laboratory operations and quality systems
Subscribe To Our Newsletter & Stay Updated
